This phase I trial studies the side effects and how well light dosimetry system works during photodynamic therapy with porfimer sodium in treating participants with malignant mesothelioma or non-small cell lung cancer with pleural disease undergoing surgery. Light dosimetry measures the amount of laser light given during photodynamic therapy. Photodynamic therapy uses a drug, such as porfimer sodium, that becomes active when it is exposed to light. The activated drug may kill tumor cells. Using light dosimetry for intraoperative photodynamic therapy may help doctors estimate how much light is delivered during photodynamic therapy and decide if the treatment should be stopped or continued.
From the blog
Mesothelioma Awareness Day is September 26, 2018
Mesothelioma Awareness Day will once again take place on September 26, marking 15 consecutive years of awareness aimed to educate and inform society about the deadly cancer caused by exposure to asbestos. Established in 2004 by the Meso Foundation, the event eventually received recognition by the House and U.S. Senate[…]
Survival Improves in Mesothelioma Patients who Received an Electricity-Based Treatment
The success of a recent Phase II clinical trial in malignant pleural mesothelioma has scientists and researchers excited about the possibility of adding a new treatment that will not only improve survival, but also improve quality of life of the cancer patient. Tumor Treating Fields, which is a therapy that[…]
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.
Asbestos Related Deaths Reportedly Double Previous Estimations In the United States
Since the dangers of asbestos exposure began to come to light over 40 years ago, regulations have been implemented to ban asbestos in most household products and to severely limit asbestos exposure in the workplace. Asbestos is a known carcinogen that causes lung cancer, asbestosis, mesothelioma, and other life-threatening diseases,[…]
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.
Sarcopenia in Relation to Overall Survival in Peritoneal Mesothelioma
Peritoneal mesothelioma only affects about 500 people each year, but its aggressive nature makes it hard to treat successfully and many who are diagnosed will on average survive only 6 to 12 months. Peritoneal mesothelioma is a cancer affecting the abdominal lining, or peritoneum, which is why it is sometimes referred[…]
CAR T-Cell Therapy Research for Mesothelioma and Other Cancers
In malignant pleural mesothelioma, mesothelin – a protein that can be over expressed in many cancers – is present in 80 percent to 90 percent of all these cases. However, it is not common to see mesothelin on mesothelial cells, which allows for potential targeted treatment. CAR T -cell therapy[…]
Empathetic Nurses Have Positive Impact on Cellular Activity in Pleural Mesothelioma Patients
A mesothelioma diagnosis and the treatment involved take a dramatic toll on the body and the mind, and with no known cure for mesothelioma, it is understandable that many feel loss of hope and despair. However, a recent study showed that having good mental health can improve treatment outcome, and[…]
Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma
This is a phase 1 dose escalation study to characterize the feasibility, safety and tolerability of MCY-M11 when administered as an intraperitoneal (IP) infusion for 3 weekly doses for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, and subjects with peritoneal mesothelioma with recurrence after prior chemotherapy.
Skip to content